References
- Kása A, Csortos C, Verin AD. Cytoskeletal mechanisms regulating vascular endothelial barrier function in response to acute lung injury. Tissue Barriers. 2015;3(1):1. doi:https://doi.org/10.4161/21688370.2014.974448.
- Makanya A, Anagnostopoulou A, Djonov V. Development and remodeling of the vertebrate blood-gas barrier. Tucker R, ed. Biomed Res Int. 2013;2013:101597. doi:https://doi.org/10.1155/2013/101597.
- Metcalfe SM. LIF and the lung’s stem cell niche: is failure to use LIF to protect against COVID-19 a grave omission in managing the pandemic? Future Virol. 2020;15(10):659–10. doi:https://doi.org/10.2217/fvl-2020-0340.
- Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi L, Camporota L. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med. 2020;46(6):1099–1102. doi:https://doi.org/10.1007/s00134-020-06033-2.
- Spadaro S, Fogagnolo A, Campo G, Zucchetti O, Verri M, Ottaviani I, Tunstall T, Grasso S, Scaramuzzo V, Murgolo F, et al. Markers of endothelial and epithelial pulmonary injury in mechanically ventilated COVID-19 ICU patients. Crit Care. 2021;25(1):74. doi:https://doi.org/10.1186/s13054-021-03499-4.
- Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, Vanstapel A, Werlein C, Stark H, Tzankov A, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19. N Engl J Med. 2020;383(2):120–128. doi:https://doi.org/10.1056/nejmoa2015432.
- Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–1418. doi:https://doi.org/10.1016/S0140-6736(20)30937-5.
- Ziegler CGK, Allon SJ, Nyquist SK, Mbano IM, Miao VN, Tzouanas CN, Cao Y, Yousif AS, Bals J, Hauser BM, et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell. 2020;181(5):1016–1035.e19. doi:https://doi.org/10.1016/j.cell.2020.04.035.
- Hayden MR. Endothelial activation and dysfunction in metabolic syndrome, type 2 diabetes and coronavirus disease 2019. J Int Med Res. 2020;48(7):030006052093974. doi:https://doi.org/10.1177/0300060520939746.
- Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA - J Am Med Assoc. 2020;324(8):782–793. doi:https://doi.org/10.1001/jama.2020.12839.
- Krischuns T, Günl F, Henschel L, Binder M, Willemsen J, Schloer S, Rescher U, Gerlt V, Zimmer G, Nordhoff C, et al. Phosphorylation of TRIM28 enhances the expression of IFN-β and proinflammatory cytokines during HPAIV infection of human lung epithelial cells. Front Immunol. 2018;9:2229. doi:https://doi.org/10.3389/fimmu.2018.02229.
- Herndon JM, Tome ME, Davis TP. Development and maintenance of the blood-brain barrier. Caplan LR, Biller J, Leary MC, editors. Primer on cerebrovascular diseases. Second. Academic Press; 2017. 51–56. https://doi.org/10.1016/B978-0-12-803058-5.00009-6.
- Wagner WL, Hellbach K, Fiedler MO, Salg GA, Wehrse E, Ziener CH, Merle U, Eckert C, Weber TF, Stiller W, et al. Microvascular changes in COVID-19. Radiologe. 2020;60(10):934–942. doi:https://doi.org/10.1007/s00117-020-00743-w.
- Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020;116(6):1097–1100. doi:https://doi.org/10.1093/CVR/CVAA078.
- Rodrigues SF, Granger DN. Blood cells and endothelial barrier function. Tissue Barriers. 2015;3(1):e978720. doi:https://doi.org/10.4161/21688370.2014.978720.
- Cardot-Leccia N, Hubiche T, Dellamonica J, Burel-Vandenbos F, Passeron T. Pericyte alteration sheds light on micro-vasculopathy in COVID-19 infection. Intensive Care Med. 2020;46(9):1777–1778. doi:https://doi.org/10.1007/s00134-020-06147-7.
- Yuksel H, Turkeli A. Airway epithelial barrier dysfunction in the pathogenesis and prognosis of respiratory tract diseases in childhood and adulthood. Tissue Barriers. 2017;5(4):e1367458. doi:https://doi.org/10.1080/21688370.2017.1367458.
- Linfield DT, Raduka A, Aghapour M, Rezaee F. Airway tight junctions as targets of viral infections: tight junctions and viral infections. Tissue Barriers Published online. 2021 February 26;9(2):1883965. doi:https://doi.org/10.1080/21688370.2021.1883965.
- Ward C, Schlingmann B, Stecenko AA, Guidot DM, Koval M. NF-кB inhibitors impair lung epithelial tight junctions in the absence of inflammation. Tissue Barriers. 2015;3(1):e982424. doi:https://doi.org/10.4161/21688370.2014.982424.
- Wang YX, Ma JR, Wang SQ, Zeng Y-Q, Zhou C-Y, Ru Y-H, Zhang L, Lu Z-G, Wu M-H, Li H, et al. Utilizing integrating network pharmacological approaches to investigate the potential mechanism of Ma Xing Shi Gan Decoction in treating COVID-19. Eur Rev Med Pharmacol Sci. 2020;24(6):3360–3384. doi:https://doi.org/10.26355/eurrev_202003_20704.
- De Maio F, Lo Cascio E, Babini G, Sali M, Della Longa S, Tilocca B, Roncada P, Arcovito A, Sanguinetti M, Scambia G, et al. Improved binding of SARS-CoV-2 envelope protein to tight junction-associated PALS1 could play a key role in COVID-19 pathogenesis. Microbes Infect. 2020;22(10):592–597. doi:https://doi.org/10.1016/j.micinf.2020.08.006.
- Tripathi A, Hazari PP, Mishra AK, Kumar B, Sagi SSK. Quercetin: a savior of alveolar barrier integrity under hypoxic microenvironment. Tissue Barriers Published online. 2021 February 26;9(2):1883963. doi:https://doi.org/10.1080/21688370.2021.1883963.
- Chen H, Lu R, Zhang YG, Sun J. Vitamin D receptor deletion leads to the destruction of tight and adherens junctions in lungs. Tissue Barriers. 2018;6(4):1–13. doi:https://doi.org/10.1080/21688370.2018.1540904.
- Hekman RM, Hume AJ, Goel RK, Abo KM, Huang J, Blum BC, Werder RB, Suder EL, Paul I, Phanse S, et al. Actionable cytopathogenic host responses of human alveolar type 2 cells to SARS-CoV-2. Mol Cell. 2020;80(6):1104–1122.e9. doi:https://doi.org/10.1016/j.molcel.2020.11.028.
- Young BM, Shankar K, Tho CK, Pellegrino AR, Heise RL. Laminin-driven Epac/Rap1 regulation of epithelial barriers on decellularized matrix. Acta Biomater. 2019;100:223–234. doi:https://doi.org/10.1016/j.actbio.2019.10.009.
- AbdelMassih A, Yacoub E, Husseiny RJ, Kamel A, Hozaien R, El Shershaby M, Rajab M, Yacoub S, Eid MA, Elahmady M, et al. Hypoxia-inducible factor (HIF): the link between obesity and COVID-19. Obes Med. 2021;22:100317. doi:https://doi.org/10.1016/j.obmed.2020.100317.
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:https://doi.org/10.1016/S0140-6736(20)30183-5.
- Neve A, Cantatore FP, Maruotti N, Corrado A, Ribatti D. Extracellular matrix modulates angiogenesis in physiological and pathological conditions. Baiguera S, ed. Biomed Res Int. 2014;2014:756078. doi:https://doi.org/10.1155/2014/756078.
- Janardhanan R, Kilari S, Leof EB, Misra S. Hyperglycemia-induced modulation of the physiognomy and angiogenic potential of fibroblasts mediated by matrix metalloproteinase-2: implications for venous stenosis formation associated with hemodialysis vascular access in diabetic milieu. J Vasc Res. 2016;52(5):334–346. doi:https://doi.org/10.1159/000443886.
- Harkema JR, Nikula KJ, Haschek WM. Respiratory System. In: Wallig MA, Haschek WM, Rousseaux CG, Bolon B, editors. Fundamentals of toxicologic pathology. Third. Academic Press; 2018. p. 351–393. doi:https://doi.org/10.1016/B978-0-12-809841-7.00014-9.
- Hasaneen NA, Cao J, Pulkoski-Gross A, Zucker S, Foda HD. Extracellular matrix metalloproteinase inducer (EMMPRIN) promotes lung fibroblast proliferation, survival and differentiation to myofibroblasts. Respir Res. 2016;17(1):17. doi:https://doi.org/10.1186/s12931-016-0334-7.
- Morgun AV, Salmin VV, Boytsova EB, Lopatina OL, Salmina AB. Molecular Mechanisms of Proteins — targets for SARS-CоV-2 (Review). Sovrem Tehnol V Med. 2020;12(6):98. doi:https://doi.org/10.17691/stm2020.12.6.11.
- Fadista J, Kraven LM, Karjalainen J, Andrews SJ, Geller F, Baillie JK, Wain LV, Jenkins RG, Feenstra B. Shared genetic etiology between idiopathic pulmonary fibrosis and COVID-19 severity. EBioMedicine. 2021:65. doi:https://doi.org/10.1016/j.ebiom.2021.103277.
- Metcalfe SM. Mesenchymal stem cells and management of COVID-19 pneumonia. Med Drug Discov. 2020;5:100019. doi:https://doi.org/10.1016/j.medidd.2020.100019
- Doglioni C, Ravaglia C, Chilosi M, Rossi G, Dubini A, Pedica F, Piciucchi S, Vizzuso A, Stella F, Maitan S, et al. Covid-19 interstitial pneumonia: histological and immunohistochemical features on cryobiopsies. Respiration. 2021;1–11. Published online. doi:https://doi.org/10.1159/000514822
- Paris AJ, Hayer KE, Oved JH, Avgousti DC, Toulmin SA, Zepp JA, Zacharias WJ, Katzen JB, Basil MC, Kremp MM, et al. STAT3–BDNF–TrkB signalling promotes alveolar epithelial regeneration after lung injury. Nat Cell Biol. 2020;22(10):1197–1210. doi:https://doi.org/10.1038/s41556-020-0569-x.
- Zhao L, Wang X, Xiong Y, Fan Y, Zhou Y, Zhu W. Correlation of autopsy pathological findings and imaging features from 9 fatal cases of COVID-19 pneumonia. Medicine (Baltimore). 2021;100(12):e25232. doi:https://doi.org/10.1097/MD.0000000000025232.
- Chilosi M, Poletti V, Ravaglia C, Rossi G, Dubini A, Piciucchi S, Pedica F, Bronte V, Pizzolo G, Martignoni G, et al. The pathogenic role of epithelial and endothelial cells in early-phase COVID-19 pneumonia: victims and partners in crime. Mod Pathol. Published online 2021 April 21. doi:https://doi.org/10.1038/s41379-021-00808-8.
- Ferreira-Gomes M, Kruglov A, Durek P, Heinrich F, Tizian C, Heinz GA, Pascual-Reguant A, Du W, Mothes R, Fan C, et al. In severe COVID-19, SARS-CoV-2 induces a chronic, TGF-β-dominated adaptive immune response. medRxiv. 2020;12(1):1961. doi:https://doi.org/10.1101/2020.09.04.20188169.
- Shin JM, Kang JH, Park JH, Yang HW, Lee HM, Park IH. Tgf-β1 activates nasal fibroblasts through the induction of endoplasmic reticulum stress. Biomolecules. 2020;10(6):1–13. doi:https://doi.org/10.3390/biom10060942.
- Kodera Y, Kohno T, Konno T, Arai W, Tsujiwaki M, Shindo Y, Chiba H, Miyakawa M, Tanaka H, Sakuma Y, et al. HMGB1 enhances epithelial permeability via p63/TGF-β signaling in lung and terminal bronchial epithelial cells. Tissue Barriers. 2020;8(4):1805997. doi:https://doi.org/10.1080/21688370.2020.1805997.
- Gowda P, Patrick S, Joshi SD, Kumawat RK, Sen E. Glycyrrhizin prevents SARS-CoV-2 S1 and Orf3a induced high mobility group box 1 (HMGB1) release and inhibits viral replication. Cytokine. 2021;142:155496. doi:https://doi.org/10.1016/j.cyto.2021.155496.
- Yu D, Ye T, Xiang Y, Shi Z, Zhang J, Lou B, Zhang F, Chen B, Zhou M. Quercetin inhibits epithelial–mesenchymal transition, decreases invasiveness and metastasis, and reverses IL-6 induced epithelial–mesenchymal transition, expression of MMP by inhibiting STAT3 signaling in pancreatic cancer cells. Onco Targets Ther. 2017;10:4719–4729. doi:https://doi.org/10.2147/OTT.S136840.
- Eapen MS, Lu W, Gaikwad AV, Bhattarai P, Chia C, Hardikar A, Haug G, Sohal SS. Endothelial to mesenchymal transition: a precursor to post-COVID-19 interstitial pulmonary fibrosis and vascular obliteration? Eur Respir J. 2020;56(4):2003167. doi:https://doi.org/10.1183/13993003.03167-2020.
- Duszyc K, Gomez GA, Schroder K, Sweet MJ, Yap AS. In life there is death: how epithelial tissue barriers are preserved despite the challenge of apoptosis. Tissue Barriers. 2017;5(4):e1345353. doi:https://doi.org/10.1080/21688370.2017.1345353.
- Morris G, Bortolasci CC, Puri BK, Olive L, Marx W, O’Neil A, Athan E, Carvalho A, Maes M, Walder K, et al. Preventing the development of severe COVID-19 by modifying immunothrombosis. Life Sci. 2021;264:118617. doi:https://doi.org/10.1016/j.lfs.2020.118617.
- Jia C, Zhang J, Chen H, Zhuge Y, Chen H, Qian F, Zhou K, Niu C, Wang F, Qiu H, et al. Endothelial cell pyroptosis plays an important role in Kawasaki disease via HMGB1/RAGE/cathespin B signaling pathway and NLRP3 inflammasome activation. Cell Death Dis. 2019;10(10):778. doi:https://doi.org/10.1038/s41419-019-2021-3.
- Viner RM, Whittaker E. Kawasaki-like disease: emerging complication during the COVID-19 pandemic. Lancet. 2020;395(10239):1741–1743. doi:https://doi.org/10.1016/S0140-6736(20)31129-6.
- Hammer S, Haeberle H, Schlensak C, Bitzer M, Malek NP, Handgretinger R, Lang P, Hörber S, Peter A, Martus P, et al. Severe SARS-CoV-2 infection inhibits fibrinolysis leading to changes in viscoelastic properties of blood clot: a descriptive study of fibrinolysis. Thromb Haemost. Published online 2021. doi:https://doi.org/10.1055/a-1400-6034
- Demopoulos C, Antonopoulou S, Theoharides TC. COVID-19, microthromboses, inflammation, and platelet activating factor. BioFactors 2020;46(6):927–933. doi:https://doi.org/10.1002/biof.1696.
- Solun B, Shoenfeld Y. Inhibition of metalloproteinases in therapy for severe lung injury due to COVID-19. Med Drug Discov. 2020;7:100052. doi:https://doi.org/10.1016/j.medidd.2020.100052.
- Sies H, Parnham MJ. Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections. Free Radic Biol Med. 2020;156:107–112. doi:https://doi.org/10.1016/j.freeradbiomed.2020.06.032.
- Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, Zhang B, Li X, Zhang L, Peng C, et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582(7811):289–293. doi:https://doi.org/10.1038/s41586-020-2223-y.
- Theoharides TC, Antonopoulou S, Demopoulos CA. Coronavirus 2019, microthromboses, and platelet activating factor. Clin Ther. 2020;42(10):1850–1852. doi:https://doi.org/10.1016/j.clinthera.2020.08.006.